Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

April 28, 2022

Study Completion Date

April 28, 2022

Conditions
Quality of LifeType 2 DiabetesMetformin+Sitagliptin
Interventions
DRUG

Metformin / Sitagliptin Oral Tablet

"Metformin and sitagliptin are oral diabetes medicines that help control blood sugar levels.~Metformin works by decreasing glucose (sugar) production in the liver and decreasing absorption of glucose by the intestines. Sitagliptin works by regulating the levels of insulin your body produces after eating.~Metformin and sitagliptin is a combination medicine that is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. metformin and sitagliptin is not for treating type 1 diabetes."

Trial Locations (1)

75330

Primary Care Diabetes Association, Karachi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Getz Pharma

INDUSTRY

NCT05167513 - Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients | Biotech Hunter | Biotech Hunter